Valproate metabolites in high-dose valproate plus phenytoin therapy

Epilepsia

Volumn 37, Issue 12, 1996, Pages 1200-1203

  Sugimoto, Tateo ^a   Muro, Hideki ^b   Woo, Man ^a   Nishida, Naoki ^a   Murakami, Kiyotaka ^c  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Moji Rousai Hospital   (Japan)

^c Department of Pediatrics   (Japan)

Author keywords

Hepatotoxicity; Phenytoin; Valproate; Oxidation; Oxidation

Indexed keywords

PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; EPILEPSY; FATTY ACID OXIDATION; HUMAN; LIVER FUNCTION; LIVER TOXICITY; PRIORITY JOURNAL;

EID: 0029811228     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00553.x     Document Type: Article

References (13)

1. Dreifuss FE, Santilli N, Langer DH, Sweeny KP, Moline KA, Melander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;36:379-85.
2. Sugimoto T, Nishida N, Yasuhara A, Ono A, Sakane Y, Matsumura T. Reye-like syndrome associated with valproic acid. Brain Dev 1983;5:334-7.
3. Murakami K, Sugimoto T, Nishida N, Kobayashi Y, Kuhara T, Matsumoto I. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy. Brain Dev 1992;14:178-81.
4. Sugimoto T, Muro H, Woo M, Nishida N, Murakami K. Metabolite profiles in patients on high dose valproate monotherapy. Epilepsy Rex 1996 (in press).
5. Tatsuhara T, Muro H, Matsuda Y, Imai Y. Determination of valproic acid and its metabolites by gas chromatography-mass spectrometry with selected ion monitoring. J Chromatogr 1987;399:183-95.
6. Siemes H, Nau H, Schultze K, et al. Valproate (VPA) metabolites in various clinical conditions of probably VPA-associated hepatotoxicity. Epilepsia 1993;34:332-46.
7. Hurst DL. Expanded therapeutic range of valproate. Pediatr Neurol 1987;3:342-4.
8. Ohtsuka Y, Amano R, Mizukawa M, Oka E, Ohtawara S. Treatment of intractable childhood epilepsy with high-dose valproate. Epilepsia 1992;33:158-64.
9. Woo M, Sugimoto T, Nishida N, et al. Valproate retard granule: efficacy and side effect. Jpn J Psychiatr Neurol 1993;47:288-90.
10. Chez MG, Bourgeois BFD, Pippenger CE, Knowles WD, Pharma-codynamic interactions between phenytoin and valproate: individual and combined antiepileptic are neurotoxic actions in mice. Clin Neuropharmacol 1994;17:32-7.
11. König SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:1005-15.
12. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit 1986;8:411-5.
13. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.